Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Progressive Multiple Cystic Changes in Both Lungs in a Patient Treated with Gefitinib for Lung Adenocarcinoma with Multiple Lung Metastases

  • Ryu, Yon Ju (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Chun, Eun Mi (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Lee, Soon Nam (Division of Hemato-Oncology, Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Shim, Sung Shin (Department of Radiology, Ewha Womans University School of Medicine)
  • Received : 2013.07.09
  • Accepted : 2014.01.02
  • Published : 2014.04.01
⟨ Previous Next ⟩

Abstract

Gefitinib is regarded as a relatively safe agent for the treatment of an advanced non-small cell lung cancer (NSCLC). Pulmonary toxicity such as interstitial lung disease associated with gefitinib is uncommon with an estimated all time incidence around 1% worldwide. Moreover, a case of gefitinib associated with pulmonary cystic changes has not been reported yet. In this report we present a case of progressive multiple air cystic changes in both lungs in a patient with NSCLC and intrapulmonary metastases who underwent a gefitinib therapy.

Keywords

References

  1. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-306 https://doi.org/10.1634/theoncologist.8-4-303
  2. Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in nonsmall- cell lung cancer. Drug Saf 2004;27:1081-1092 https://doi.org/10.2165/00002018-200427140-00002
  3. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006;17:372-379 https://doi.org/10.1093/annonc/mdj057
  4. Hotta K, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005;11:417-424 https://doi.org/10.1097/00130404-200509000-00010
  5. Teramoto S, Yamamoto H, Ouchi Y. Clinical efficacy and toxicity of gefitinib in patients with lung cancer. Lancet 2003;361:1992-1993
  6. Nagaria NC, Cogswell J, Choe JK, Kasimis B. Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol 2005;23:2423-2424 https://doi.org/10.1200/JCO.2005.04.055
  7. Topal NB, Oruc E, Gokalp G, Topal U. Atypical pulmonary metastases: radiologic appearances. Indian J Radiol Imaging 2007;17:181-185 https://doi.org/10.4103/0971-3026.34723
  8. Lee JC, Kim CH, Koh JS, Baek HJ, Choe DH. Lung cancer presenting as an asymptomatic pneumatocele. Intern Med 2008;47:1757-1758 https://doi.org/10.2169/internalmedicine.47.1387
  9. Barnardt P, du Toit J. The radiological appearance of metastatic cystic lesions. SA Journal of Radiology 2011:131-133
  10. Zee YK, Chin TM, Wong AS. Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer. J Clin Oncol 2009;27:e145-e146 https://doi.org/10.1200/JCO.2009.22.4501
  11. Danson S, Blackhall F, Hulse P, Ranson M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf 2005;28:103-113 https://doi.org/10.2165/00002018-200528020-00002
  12. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500 https://doi.org/10.1126/science.1099314